膜联蛋白A1在小细胞肺癌骨转移中的作用及分子机制的研究
摘要
肺癌是目前世界上最常见的恶性肿瘤之一，其发病率和死亡率在许多国家都位居前列。肺癌骨转移是肺癌患者中经常出现的严重并发症。伴随着骨转移的发生，肺癌患者的生存质量和生存时间都将受到严重威胁。然而，目前对肺癌骨转移的研究相对较少，尚不能阐明肺癌骨转移发生与发展的机制。因此，临床上可用于肺癌骨转移治疗的药物和手段都非常有限。在本实验室以往的蛋白质组学研究中，我们发现膜联蛋白A1在高骨转移小细胞肺癌细胞中呈高表达，提示膜联蛋白A1可能与肺癌骨转移相关。为了探明膜联蛋白A1在肺癌骨转移发生发展中的作用，在国家自然科学基金的资助下，我们通过一系列实验对本课题进行了研究。
目的：
应用细胞与动物模型，分别在体外和体内两方面观察膜联蛋白A1在小细胞肺癌细胞中的生物学作用；揭示膜联蛋白A1与小细胞肺癌骨转移的关系；初步探讨膜联蛋白A1在小细胞肺癌骨转移中作用的分子机制；为临床开发新的防治肺癌骨转移的药物与方法提供理论依据。
方法：
1、应用Real-time PCR和Western blot方法检测相似遗传背景不同骨转移能力的小细胞肺癌细胞株中膜联蛋白A1的表达差异；
2、构建膜联蛋白A1过表达和siRNA慢病毒表达载体，并分别建立膜联蛋白A1表达上调或抑制的小细胞肺癌细胞株，通过MTT、平板克隆形成、流式细胞检测细胞周期、Transwell检测细胞体外侵袭与转移、体外骨黏附实验等方法在体外观察膜联蛋白A1在小细胞肺癌细胞株中的生物学作用；
3、应用NOD/SCID鼠作为动物模型，观察不同膜联蛋白A1表达水平的小细胞肺癌细胞骨转移形成能力，揭示膜联蛋白A1与小细胞肺癌骨转移的关系；
4、通过Real-time PCR、Western blot和Elisa检测等手段验证膜联蛋白A1与小细胞肺癌细胞中甲状旁腺素相关蛋白（PTHrP）合成与分泌的关系，并通过TGF-β诱导，观察膜联蛋白A1对小细胞肺癌细胞TGF-β/Smad信号通路的影响，初步阐明膜联蛋白A1在小细胞肺癌骨转移中作用的分子机制。
结果：
1、膜联蛋白A1在高骨转移潜能小细胞肺癌细胞株SBC-5中的表达高于其在相似遗传背景的低骨转移潜能细胞株SBC-3中的表达，提示膜联蛋白A1可能是一个新的肺癌骨转移相关蛋白；
2、体外实验证实膜联蛋白A1具有促进小细胞肺癌细胞增殖、侵袭与转移以及黏附骨片的作用；
3、在NOD/SCID鼠平台上证实膜联蛋白A1具有促进小细胞肺癌细胞在体内形成骨转移灶的作用；
4、膜联蛋白A1可促进小细胞肺癌细胞中PTHrP的合成与分泌。在体外TGF-β诱导下，膜联蛋白A1可通过促进Smad2的磷酸化来增强TGF-β诱导细胞分泌PTHrP的能力，从而增强肺癌骨转移中PTHrP-TGF-β正反馈恶性循环的作用。
结论：
膜联蛋白A1是一个新的肺癌骨转移相关蛋白，它可以增强小细胞肺癌细胞的增殖、侵袭与迁移以及骨黏附能力，并能促进肿瘤细胞在NOD/SCID鼠中形成骨转移。膜联蛋白A1可促进小细胞肺癌细胞合成与分泌PTHrP，并可以通过增加细胞中Smad2的磷酸化来上调TGF-β诱导下细胞分泌PTHrP的能力，从而增强肺癌骨转移过程中的PTHrP-TGF-β正反馈恶性循环的作用，这可能是膜联蛋白A1促进小细胞肺癌骨转移的分子机制之一。
Globally, Lung cancer is the major cause of malignancy-related mortality, and itsincidence is on the rise in many countries. Bone Metastasis is one of the most seriouscomplications of lung cancer. Bone metastases are often associated with skeletal-relatedevents, which may decrease the quality of life for patients. Due to less known about themolecular mechanism of bone metastasis, little progress has been made in treating skeletalmetastasis, currently. In previous proteomic study, we found that Annexin A1wasoverexpressed in bone-metastatic small cell lung cancer (SCLC) cells. It indicated thatAnnexin A1might play roles in osteotropism metastasis of SCLC. In our present study, weperform a list of experiments to confirm this hypothesis.
Purpose
To observe the biofunction of Annexin A1in SCLC cells in vitro and in vivo, prove that the Annexin A1is closely related to the bone metastasis of SCLC, and explore themolecular mechanism of Annexin A1related bone metastases.
Methods
1. Using Real-time PCR and Western blot assays to demonstrate the expression ofAnnexin A1in SCLC cell lines with different capability of bone metastasis.
2. Constructing the Lentiviral vector mediated overexpression or siRNA targeteddownregulation of Annexin A1in SCLC cells, and observing the cell behavior includingproliferation, cell cycle, invasion and migration and the ability of bone adhesion in vitro.
3. Using NOD/SCID mouse as bone metastasis model to detect the bone metastaticability of SCLC cells with different Annexin A1expression level.
4. In order to explore the molecular mechanism of Annexin A1related bonemetastases, Real-time PCR, Western blot and Elisa assays were performed to detect theexpression of PTHrP induced by Annexin A1in different SCLC cells, and observe theeffection of Annexin A1on TGF-β/Smad signal passway in SCLC cells with or withoutTGF-β incubation.
Results
1. Annexin A1is overexpressed in bone-metastatic SCLC cell line SBC-5. Itindicates that the Annexin A1maybe associated with bone metastases in SCLC.
2. Annexin A1is able to enhance SCLC cells proliferation，invasion, migration andbone adhesion in vitro.
3. Annexin A1has the potential to promote the bone-metastatic ability of SCLCcells in NOD/SCID mouse.
4. Annexin A1has ability to upregulate the synthesis and secretion of PTHrP inSCLC cells. With TGF-β incubation, Annexin A1is able to increase the secretion ofPTHrP through enhancing the phosphorylation of Smad2in SCLC cells.
Conclusion
Annexin A1has the potential to promote the SCLC cells proliferaton, invasion,migration and bone adhesion in vitro and bone metastases in vivo. Annexin A1induced overexpression of PTHrP is involved in Annexin A1related bone metastases in SCLCcells. Annexin A1is able to enhance the PTHrP-TGF-β vicious cycle in tumor bonemetastasis though TGF-β/Smad passway.
目的：
应用细胞与动物模型，分别在体外和体内两方面观察膜联蛋白A1在小细胞肺癌细胞中的生物学作用；揭示膜联蛋白A1与小细胞肺癌骨转移的关系；初步探讨膜联蛋白A1在小细胞肺癌骨转移中作用的分子机制；为临床开发新的防治肺癌骨转移的药物与方法提供理论依据。
方法：
1、应用Real-time PCR和Western blot方法检测相似遗传背景不同骨转移能力的小细胞肺癌细胞株中膜联蛋白A1的表达差异；
2、构建膜联蛋白A1过表达和siRNA慢病毒表达载体，并分别建立膜联蛋白A1表达上调或抑制的小细胞肺癌细胞株，通过MTT、平板克隆形成、流式细胞检测细胞周期、Transwell检测细胞体外侵袭与转移、体外骨黏附实验等方法在体外观察膜联蛋白A1在小细胞肺癌细胞株中的生物学作用；
3、应用NOD/SCID鼠作为动物模型，观察不同膜联蛋白A1表达水平的小细胞肺癌细胞骨转移形成能力，揭示膜联蛋白A1与小细胞肺癌骨转移的关系；
4、通过Real-time PCR、Western blot和Elisa检测等手段验证膜联蛋白A1与小细胞肺癌细胞中甲状旁腺素相关蛋白（PTHrP）合成与分泌的关系，并通过TGF-β诱导，观察膜联蛋白A1对小细胞肺癌细胞TGF-β/Smad信号通路的影响，初步阐明膜联蛋白A1在小细胞肺癌骨转移中作用的分子机制。
结果：
1、膜联蛋白A1在高骨转移潜能小细胞肺癌细胞株SBC-5中的表达高于其在相似遗传背景的低骨转移潜能细胞株SBC-3中的表达，提示膜联蛋白A1可能是一个新的肺癌骨转移相关蛋白；
2、体外实验证实膜联蛋白A1具有促进小细胞肺癌细胞增殖、侵袭与转移以及黏附骨片的作用；
3、在NOD/SCID鼠平台上证实膜联蛋白A1具有促进小细胞肺癌细胞在体内形成骨转移灶的作用；
4、膜联蛋白A1可促进小细胞肺癌细胞中PTHrP的合成与分泌。在体外TGF-β诱导下，膜联蛋白A1可通过促进Smad2的磷酸化来增强TGF-β诱导细胞分泌PTHrP的能力，从而增强肺癌骨转移中PTHrP-TGF-β正反馈恶性循环的作用。
结论：
膜联蛋白A1是一个新的肺癌骨转移相关蛋白，它可以增强小细胞肺癌细胞的增殖、侵袭与迁移以及骨黏附能力，并能促进肿瘤细胞在NOD/SCID鼠中形成骨转移。膜联蛋白A1可促进小细胞肺癌细胞合成与分泌PTHrP，并可以通过增加细胞中Smad2的磷酸化来上调TGF-β诱导下细胞分泌PTHrP的能力，从而增强肺癌骨转移过程中的PTHrP-TGF-β正反馈恶性循环的作用，这可能是膜联蛋白A1促进小细胞肺癌骨转移的分子机制之一。
Globally, Lung cancer is the major cause of malignancy-related mortality, and itsincidence is on the rise in many countries. Bone Metastasis is one of the most seriouscomplications of lung cancer. Bone metastases are often associated with skeletal-relatedevents, which may decrease the quality of life for patients. Due to less known about themolecular mechanism of bone metastasis, little progress has been made in treating skeletalmetastasis, currently. In previous proteomic study, we found that Annexin A1wasoverexpressed in bone-metastatic small cell lung cancer (SCLC) cells. It indicated thatAnnexin A1might play roles in osteotropism metastasis of SCLC. In our present study, weperform a list of experiments to confirm this hypothesis.
Purpose
To observe the biofunction of Annexin A1in SCLC cells in vitro and in vivo, prove that the Annexin A1is closely related to the bone metastasis of SCLC, and explore themolecular mechanism of Annexin A1related bone metastases.
Methods
1. Using Real-time PCR and Western blot assays to demonstrate the expression ofAnnexin A1in SCLC cell lines with different capability of bone metastasis.
2. Constructing the Lentiviral vector mediated overexpression or siRNA targeteddownregulation of Annexin A1in SCLC cells, and observing the cell behavior includingproliferation, cell cycle, invasion and migration and the ability of bone adhesion in vitro.
3. Using NOD/SCID mouse as bone metastasis model to detect the bone metastaticability of SCLC cells with different Annexin A1expression level.
4. In order to explore the molecular mechanism of Annexin A1related bonemetastases, Real-time PCR, Western blot and Elisa assays were performed to detect theexpression of PTHrP induced by Annexin A1in different SCLC cells, and observe theeffection of Annexin A1on TGF-β/Smad signal passway in SCLC cells with or withoutTGF-β incubation.
Results
1. Annexin A1is overexpressed in bone-metastatic SCLC cell line SBC-5. Itindicates that the Annexin A1maybe associated with bone metastases in SCLC.
2. Annexin A1is able to enhance SCLC cells proliferation，invasion, migration andbone adhesion in vitro.
3. Annexin A1has the potential to promote the bone-metastatic ability of SCLCcells in NOD/SCID mouse.
4. Annexin A1has ability to upregulate the synthesis and secretion of PTHrP inSCLC cells. With TGF-β incubation, Annexin A1is able to increase the secretion ofPTHrP through enhancing the phosphorylation of Smad2in SCLC cells.
Conclusion
Annexin A1has the potential to promote the SCLC cells proliferaton, invasion,migration and bone adhesion in vitro and bone metastases in vivo. Annexin A1induced overexpression of PTHrP is involved in Annexin A1related bone metastases in SCLCcells. Annexin A1is able to enhance the PTHrP-TGF-β vicious cycle in tumor bonemetastasis though TGF-β/Smad passway.
引文
[1] Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics.CA Cancer J Clin.2011Mar-Apr;61(2):69-90.
[2] Lam WK, White NW, Chan-Yeung MM. Lung cancer epidemiology and risk factorsin Asia and Africa. Int J Tuberc Lung Dis.2004Sep;8(9):1045-57..
[3] Jackman DM, Johnson BE. Small-cell lung cancer. Lancet.2005Oct15-21;366(9494):1385-96.
[4] National Cancer Institute. SEER Cancer Statistics Review,1975–2006.http://seer.cancer.gov/csr/1975-2006(accessed Feb7,2011).
[5] Devesa SS, Bray F, Vizcaino AP, Parkin DM. International lung cancer trends byhistologic type: male: female differences diminishing and adenocarcinoma rising. IntJ Cancer.2005Nov1;117(2):294-9.
[6] Haddadin S, Perry MC. History of small-cell lung cancer. Clin Lung Cancer.2011Mar;12(2):87-93.
[7] Rove KO, Crawford ED. Metastatic cancer in solid tumors and clinical outcome:skeletal-related events. Oncology (Williston Park).2009Dec;23(14Suppl5):21-7.
[8]刘陶文，李俊喜。恶性肿瘤骨转移的诊断。华夏医学。2005年第6期1068-1069页。
[9]吴晓徽，陆汉魁。骨代谢指标在肿瘤骨转移诊治中的应用。肿瘤。2007年第6期505-507页。
[10] Sun JM, Ahn JS, Lee S, Kim JA, Lee J, Park YH, Park HC, Ahn MJ, Ahn YC, ParkK. Predictors of skeletal-related events in non-small cell lung cancer patients withbone metastases. Lung Cancer.2011Jan;71(1):89-93.
[11]李大为，王勤。骨转移癌的外科治疗。中医正骨。2007年第11期43-45页。
[12]陶衍能。恶性肿瘤骨转移的放射性治疗概况。医学文选。2006年第1期160-162页。
[13] Flanagan AM, Chambers TJ. Inhibition of bone resorption by bisphosphonates:interactions between bisphosphonates, osteoclasts, and bone. Calcif Tissue Int.1991Dec;49(6):407-15..
[14] Oades GM, Coxon J, Colston KW. The potential role of bisphosphonates in prostatecancer. Prostate Cancer Prostatic Dis.2002;5(4):264-72..
[15] Valachis A, Polyzos NP, Georgoulias V, Mavroudis D, Mauri D. Lack of evidencefor fracture prevention in early breast cancer bisphosphonate trials: a meta-analysis.Gynecol Oncol.2010Apr;117(1):139-45.
[16] King AE, Umland EM. Osteonecrosis of the jaw in patients receiving intravenous ororal bisphosphonates. Pharmacotherapy.2008May;28(5):667-77.
[17] Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, Lichinitser M,Fujiwara Y, Yardley DA, Viniegra M, Fan M, Jiang Q, Dansey R, Jun S, Braun A.Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastasesin Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study. JClin Oncol.2010Dec10;28(35):5132-9.
[18] Kaplan RN, Rafii S, Lyden D. Preparing the "soil": the premetastatic niche. CancerRes.2006Dec1;66(23):11089-93.
[19] Yin JJ, Pollock CB, Kelly K. Mechanisms of Cancer metastasis to the bone. CellRes.2005Jan;15(1):57-62.
[20] Yoneda T, Hiraga T. Crosstalk between cancer cells and bone microenvironment inbone metastasis. Biochem Biophys Res Commun.2005Mar18;328(3):679-87.
[21] Kingsley LA, Fournier PG, Chirgwin JM, Guise TA. Molecular biology of bonemetastasis. Mol Cancer Ther.2007Oct;6(10):2609-17.
[22] Acuff HB, Carter KJ, Fingleton B, Gorden DL, Matrisian LM. Matrixmetalloproteinase-9from bone marrow-derived cells contributes to survival but notgrowth of tumor cells in the lung microenvironment. Cancer Res.2006Jan1;66(1):259-66.
[23] Li M, Amizuka N, Takeuchi K, Freitas PH, Kawano Y, Hoshino M, Oda K,Nozawa-Inoue K, Maeda T. Histochemical evidence of osteoclastic degradation ofextracellular matrix in osteolytic metastasis originating from human lung smallcarcinoma(SBC-5)cells. Microsc Res Tech.2006Feb;69(2):73-83.
[24] Hsua CP, Shen GH, Ko JL. Matrix metalloproteinase-13expression is associatedwith bone marrow micro involvement and prognosis in non-small cell lung cancer.Lung Cancer.2006Jun;52(3):349-57.
[25]丁红仙。肿瘤免疫逃逸机制的研究进展。海峡药学。2008年第7期12-14页。
[26] Nakamura ES, Koizumi K, Kobayashi M, Saitoh Y, Arita Y, Nakayama T, SakuraiH, Yoshie O, Saiki I. RANKL2induced CCL22/macrop-hage2derived chemokineproduced from osteoclasts potentially promotes the bone metastasis of lung cancerexp ressing its receptor CCR4. Clin Exp Metastasis.2006;23(1):9-18.
[27] Phillips RJ, Burdick MD, Lutz M, Belperio JA, Keane MP, Strieter RM. Thestromal derived Factor1/CXCL12-CXC chemokine receptor-4biological axis innon small cell lung cancer metastases. Am J Respir Crit Care Med.2003Jun15;167(12):1676-86.
[28] Roodman GD. Mechanisms of bone metastasis. N Engl J Med.2004Apr15;350(16):1655-64.ngl J Med,2004,350(16):1655-1664.
[29] Martin TA, Harrison G, Mansel RE, Jiang WG. The role of the CD44／erzincomplex in cancer metastasis．Crit Rev Oncol Hematol.2003May;46(2):165-86.
[30] Hill A, McFarlane S, Johnston PG, Waugh DJ. The emerging role of CD44inregulating skeletal micrometastasis．Cancer Lett.2006Jun8;237(1):1-9.
[31] Felding-habermann B. Integrin adhesion receptors in tumor metastasis．Clin ExpMetastasis.2003;20(3):203-13.
[32] Li M, Amizuka N, Takeuchi K, Freitas PH, Kawano Y, Hoshino M, Oda K,Nozawa-Inoue K, Maeda T. Histochemical evidence of osteoclastic degradation ofextracellularmatrix in osteolytic metastasis originating from human lung smallcarcinoma (SBC-5) cells. Microsc Res Tech.2006Feb;69(2):73-83.
[33] Guise TA, Mohammad KS, Clines G, Stebbins EG, Wong DH, Higgins LS, VessellaR, Corey E, Padalecki S, Suva L, Chirgwin JM. Basic mechanisms responsible forosteolytic and osteoblastic bone metastases. Clin Cancer Res.2006Oct15;12(20Pt2):6213s-6216s.
[34] Roodman GD. Biology of osteoclast activation in cancer. J Clin Oncol.2001Aug1;19(15):3562-71.
[35] Guise TA, Yin JJ, Taylor SD, Kumagai Y, Dallas M, Boyce BF, Yoneda T, MundyGR. Evidence for a causal role of parathyroid hormone-related protein in thepathogenesis of human breast cancer-mediated osteoysis. J Clin Invest.1996Oct1;98(7):1544-9.
[36] Miki T, Yano S, Hanibuchi M, Kanematsu T, Muguruma H, Sone S. Parathyroidhormone-related protein (PTHrP) is responsible for production of bone metastasis,but not visceral metastasis, by human small cell lung Cancer SBC-5cells in naturalkiller cell-depleted SCID mice. Int J Cancer.2004Feb10;108(4):511-5.
[37] Cai Z, Chen Q, Chen J, Lu Y, Xiao G, Wu Z, Zhou Q, Zhang J. Monocytechemotactic protein1promotes lung cancer-induced bone resorptive lesions in vivo.Neoplasia.2009Mar;11(3):228-36.
[38] Choi SJ, Oba Y, Gazitt Y, Alsina M, Cruz J, Anderson J, Roodman GD. Antisenseinhibition of macrophage inflammatory protein1-alpha blocks bone destruction in amodel of myeloma bone disease. J Clin Invest.2001Dec;108(12):1833-41.
[39] Muguruma H, Yano S, Kakiuchi S, Uehara H, Kawatani M, Osada H, Sone S.Reveromycin A inhibits osteolytic bone metastasis of small cell lung cancer cells,SBC-5, through an antiosteoclastic activity. Clin Cancer Res.2005Dec15;11(24Pt1):8822-8.
[40] Miki T, Yano S, Hanibuchi M, Sone S. Bone metastasis model with multiorgandissemination of human small-cell lung Cancer (SBC-5) cells in natural killercell-depleted SCID mice. Oncol Res.2000;12(5):209-17.
[41] Zhang H, Yano S, Miki T, Goto H, Kanematsu T, Muguruma H, Uehara H, Sone S.A novel bisphosphonate minodronate (YM529) specifically inhibits osteolytic bonemetastasis produced by human small-cell lung cancer cells in NK-cell depletedSCID mice. Clin Exp Metastasis.2003;20(2):153-9.
[42] Yano S, Zhang H, Hanibuchi M, Miki T, Goto H, Uehara H, Sone S. CombinedTherapy with a New Bisphosphonate, Minodronate (YM529), and Chemotherapyfor Multiple Organ Metastases of Small Cell Lung Cancer Cells in Severe CombinedImmunodeficient Mice. Clin Cancer Res.2003Nov1;9(14):5380-5.
[43] Goto H, Yano S, Zhang H, Matsumori Y, Ogawa H, Blakey DC, Sone S. Activity ofa new vascular targeting agent, ZD6126, in pulmonary metastases by human lungadenocarcinoma in nude mice. Cancer Res.2002Jul1;62(13):3711-5.
[44] Zheng R, Yano S, Zhang H, Nakataki E, Tachibana I, Kawase I, Hayashi S, Sone S.CD9over-expression suppressed the liver metastasis and malignant ascites viainhibition of proliferation and motility of small-cell lung cancer cells in NKcell-depleted SCID mice. Oncol Res.2005;15(7-8):365-72.
[45] Fatimathas L，Moss SE．Annexins as disease modifiers．Histol Histopathol.2010Apr;25(4):527-32.
[46] Gerke V, Moss SE. Annexin: from structure to function. Physiol Rev.2002Apr;82(2):331-71.
[47] Gerke V, Creutz CE, Moss SE．Annexins：linking Ca2+signaling to membranedynamics．Nat Rev Mol Cell Biol.2005Jun;6(6):449-61.
[48] Flower RJ，Blackwell GJ．Antiinflammatory steroids induce biosynthesis of aphospholipase A2inhibitor which prevents prostaglandin generation．Nature.1979Mar29;278(5703):456-9.
[49] Kim SW, Rhee HJ, Ko J, Kim YJ, Kim HG, Yang JM, Choi EC, Na DS. Inhibitionof cytotoxic phospho lipase A2by annexin I: Specific interaction model andmapping of the interaction site. J Biol Chem.2001May11;276(19):15712-9.
[50] Croxtall JD, Choudhury Q, Flower RJ. Inhibitory effect of peptides derived from theN-terminus of lipocortin1on arachidonic acid release and proliferation in the A549cell line: identification of E-Q-E-Y-V as a crucial component. Br J Pharmacol.1998Mar;123(5):975-83.
[51] Ferlazzo V, D'Agostino P, Milano S, Caruso R, Feo S, Cillari E, Parente L.Anti-inflammatory effects of annexin1: stimulation of IL-10release and inhibitionof nitricoxide synthesis. Int Immunopharmacol.2003Oct;3(10-11):1363-9.
[52] Yona S, Ward B, Buckingham JC, Perretti M, Flower RJ. Macrophage biology inthe AnxA1-/-mouse. Prostaglandins Leukot Essent Fatty Acids.2005Feb;72(2):95-103.
[53] Chen Z, Yoshihara E, Son A, Matsuo Y, Masutani H, Sugie K, Maeda M, Yodoi J.Differential roles of Annexin A1(ANXA1/lipocortin-1/lipomodulin) andthioredoxin binding protein-2(TBP-2/VDUP1/TXNIP) in glucocorticoid signalingof HTLV-I-transformed T cells. Immunol Lett.2010Jun15;131(1):11-8.
[54] Hayhoe RP, Kamal AM, Solito E, Flower RJ, Cooper D, Perretti M. Annexin1andits bioactive peptide inhibit neutrophil-endothelium interactions under flow:indication of distinct receptor involvement. Blood.2006Mar1;107(5):2123-30.
[55] Rhee HJ, Kim GY, Huh JW, Kim SW, Na DS. Annexin I is a stress protein inducedby heat, oxidative stress and a sulfhydryl-reactive agent. Eur J Biochem.2000Jun;267(11):3220-5.
[56] Li G, He S, Chang L, Lu H, Zhang H, Zhang H, Chiu J. GADD45α and annexin A1are involved in the apoptosis of HL-60induced by resveratrol. Phytomedicine.2011Jun15;18(8-9):704-9.
[57] D'Acunto CW, Fontanella B, Rodriquez M, Taddei M, Parente L, Petrella A.Histone deacetylase inhibitor FR235222sensitizes human prostate adenocarcinomacells to apoptosis through up-regulation of Annexin A1. Cancer Lett.2010Sep1;295(1):85-91.
[58] Petrella A, Festa M, Ercolino SF, Zerilli M, Stassi G, Solito E, Parente L. Inductionof annexin-1during TRAIL-induced apoptosis in thyroid carcinoma cells. CellDeath Differ.2005Oct;12(10):1358-60.
[59] Patel DM, Ahmad SF, Weiss DG, Gerke V, Kuznetsov SA. Annexin A1is a newfunctional linker between actin filaments and phagosomes during phagocytosis. JCell Sci.2011Feb15;124(Pt4):578-88.
[60] Damazo AS, Sampaio AL, Nakata CM, Flower RJ, Perretti M, Oliani SM.Endogenous annexin A1counter-regulates bleomycin-induced lung fibrosis. BMCImmunol.2011Oct19;12:59..
[61] Dreier R, Schmid KW, Gerke V, Riehemann K. Differential expression of annexinⅠ, Ⅱand Ⅳ in human tissues: An immunohistochemical study. Histochem CellBiol.1998Aug;110(2):137-48..
[62] Bai XF, Ni XG, Zhao P, Liu SM, Wang HX, Guo B, Zhou LP, Liu F, Zhang JS,Wang K, Xie YQ, Shao YF, Zhao XH. Overexpression of annexin1in pancreaticcancer and its clinical significance. World J Gastroenterol.2004May15;10(10):1466-70.
[63] Falini B, Tiacci E, Liso A, Basso K, Sabattini E, Pacini R, Foa R, Pulsoni A, DallaFavera R, Pileri S. Simple diagnostic assay for hairy cell leukaemia byimmunocytochemical detection of annexin A1(ANXA1). Lancet.2004Jun5;363(9424):1869-70.
[64] Hummerich L, Müller R, Hess J, Kokocinski F, Hahn M, Fürstenberger G, Mauch C,Lichter P, Angel P. Identification of novel tumour-associated genes differentiallyexpressed in the process of squamous cell cancer development. Oncogene.2006Jan5;25(1):111-21.
[65] Schaeffer EM, Marchionni L, Huang Z, Simons B, Blackman A, Yu W, ParmigianiG, Berman DM. Androgen-induced programs for prostate epithelial growth andinvasion arise in embryogenesis and are reactivated in cancer. Oncogene.2008Dec4;27(57):7180-91.
[66] Xia SH, Hu LP, Hu H, Ying WT, Xu X, Cai Y, Han YL, Chen BS, Wei F, Qian XH,Cai YY, Shen Y, Wu M, Wang MR. Three isoforms of annexin I are preferentiallyexpressed in normal esophageal epithelia but downregulated in esophagealsquamous cell carcinomas. Oncogene.2002Sep26;21(43):6641-8.
[67] Garcia Pedrero JM, Fernandez MP, Morgan RO, Herrero Zapatero A, Gonzalez MV,Suarez Nieto C, Rodrigo JP. Annexin A1down-regulation in head and neck canceris associated with epithelial differentiation status. Am J Pathol.2004Jan;164(1):73-9.
[68] Koike H, Uzawa K, Nakashima D, Shimada K, Kato Y, Higo M, Kouzu Y, Endo Y,Kasamatsu A, Tanzawa H. Identification of differentially expressed proteins in oralsquamous cell carcinoma using a global proteomic approach. Int J Oncol.2005Jul;27(1):59-67.
[69] Silistino-Souza R, Rodrigues-Lisoni FC, Cury PM, Maniglia JV, Raposo LS, TajaraEH, Christian HC, Oliani SM. Annexin1: differential expression in tumor and mastcells in human larynx cancer. Int J Cancer.2007Jun15;120(12):2582-9.
[70] Shen D, Nooraie F, Elshimali Y, Lonsberry V, He J, Bose S, Chia D, Seligson D,Chang HR, Goodglick L. Decreased expression of annexin A1is correlated withbreast cancer development and progression as determined by a tissue microarrayanalysis. Hum Pathol.2006Dec;37(12):1583-91.
[71] Mussunoor S, Murray GI. The role of annexins in tumor development andprogression. J Pathol.2008Oct;216(2):131-40.
[72] Violette SM, King I, Browning JL, Pepinsky RB, Wallner BP, Sartorelli AC. Roleof lipocortin1in the glucocorticoid induction of the terminal differentiation of ahuman squamous carcinoma．Cell Physiol.1990Jan;142(1):70-7．
[73] Masaki T, Tokuda M, Ohnishi M, Watanabe S, Fujimura T, Miyamoto K, Itano T,Matsui H, Arima K, Shirai M, Maeba T, Sogawa K, Konishi R, Taniguchi K,Hatanaka Y, Hatase O, Nishioka M．Enhanced expression of the protein kinasesubstrate annexin in human hepatocellular carcinoma． Hepatology.1996Jul;24(1):72-81．
[74] Paweletz CP, Ornstein DK, Roth MJ, Bichsel VE, Gillespie JW, Calvert VS, VockeCD, Hewitt SM, Duray PH, Herring J, Wang QH, Hu N, Linehan WM, Taylor PR,Liotta LA, Emmert-Buck MR, Petricoin EF3rd．Loss of Annexin1correlates withearly onset of tumorigenesis in esophageal and prostate carcinoma．Cancer Res.2000Nov15;60(22):6293-7．
[75] Pencil SD, Toth M. Elevated levels of annexin I protein in vitro and in vivo in ratand human mammary adenocarcinoma. Clin Exp Metastasis.1998Feb;16(2):113-21.
[76] de Graauw M, van Miltenburg MH, Schmidt MK, Pont C, Lalai R, Kartopawiro J,Pardali E, Le Dévédec SE, Smit VT, van der Wal A, Van't Veer LJ, Cleton-JansenAM, ten Dijke P, van de Water B. Annexin A1regulates TGF-beta signaling andpromotes metastasis formation of basal-like breast cancer cells. Proc Natl Acad SciU S A.2010Apr6;107(14):6340-5.
[77] Cicek M, Samant RS, Kinter M, Welch DR, Casey G. Identification of metastasisassociated proteins through protein analysis of metastatic MDA-MB-435andmetastasis-suppressed BRMS1transfected MDA-MB-435cells. Clin Exp Metastasis.2004;21(2):149-57..
[78] Cao Y, Li Y, Edelweiss M, Arun B, Rosen D, Resetkova E, Wu Y, Liu J, Sahin A,Albarracin CT. Loss of annexin A1expression in breast cancer progression. ApplImmunohistochem Mol Morphol.2008Dec;16(6):530-4.
[79] Yu G, Wang J, Chen Y, Wang X, Pan J, Li Q, Xie K. Tissue microarray analysisreveals strong clinical evidence for a close association between loss of annexin A1expression and nodal metastasis in gastric cancer. Clin Exp Metastasis.2008;25(7):695-702..
[80]曲利娟，丁彦青，梁莉，余英豪。利用2-DE和MALDI-TOP-MS在人大肠癌高低转移潜能细胞株中筛选转移相关蛋白。福州总医院学报。2008年第B12期365-368页。
[81] Babbin BA, Lee WY, Parkos CA, Winfree LM, Akyildiz A, Perretti M, Nusrat A.AnxA1regulates SKCO-15cell invasion by signaling through formyl peptidereceptors. J Biol Chem.2006Jul14;281(28):19588-99.
[82]崔杰峰，刘银坤，代智，周海君，宋海燕，张丽君，张予，孙瑞霞，陈洁，汤钊猷。转移潜能不同人肝癌细胞系差异蛋白Annexin1的功能解析。生物化学与生物物理进展。2005年第12期1141-1149页。
[83] Wu W, Tang X, Hu W, Lotan R, Hong WK, Mao L. Identification and validation ofmetastasis-associated proteins in head and neck cancer cell lines by two-dimensionalelectrophoresis and mass spectrometry. Clin Exp Metastasis.2002;19(4):319-26.
[84] Rondepierre F, Bouchon B, Papon J, Bonnet-Duquennoy M, Kintossou R, Moins N,Maublant J, Madelmont JC, D'Incan M, Degoul F. Proteomic studies of B16lines:Involvement of Annexin A1in melanoma dissemination. Biochim Biophys Acta.2009Jan;1794(1):61-9.
[85] Cheng AL, Huang WG, Chen ZC, Peng F, Zhang PF, Li MY, Li F, Li JL, Li C, Yi H,Yi B, Xiao ZQ. Identification of Novel Nasopharyngeal Carcinoma Biomarkers byLaser Capture Microdissection and Proteomic Analysis. Clin Cancer Res.2008Jan15;14(2):435-45.
[86] Zimmermann U, Woenckhaus C, Teller S, Venz S, Langheinrich M, Protzel C,Maile S, Junker H, Giebel J. Expression of annexin A1in conventional renal cellcarcinoma (CRCC) correlates with tumour stage, Fuhrman grade, amount ofeosinophilic cells and clinical outcome. Histol Histopathol.2007May;22(5):527-34.
[87] Wang Y, Serfass L, Roy MO, Wong J, Bonneau AM, Georges E. Annexin-Iexpression modulates drug resistance in tumor cells. Biochem Biophys ResCommun.2004Feb6;314(2):565-70.
[88] Wang KL, Wu TT, Resetkova E, Wang H, Correa AM, Hofstetter WL, Swisher SG,Ajani JA, Rashid A, Hamilton SR, Albarracin CT. Expression of annexin A1inesophageal and esophagogastric junction adenocarcinomas:association with pooroutcome． Clin Cancer Res.2006Aug1;12(15):4598-604．
[89] Biaoxue R, Xiling J, Shuanying Y, Wei Z, Xiguang C, Jinsui W, Min Z.Upregulation of Hsp90-beta and annexin A1correlates with poor survival andlymphatic metastasis in lung cancer patients. J Exp Clin Cancer Res.2012Aug28;31:70.
[90]胡振红，黄瑊，李振华，李晓栩，傅祖红，刘海潮，官立彬。低氧上调肺腺癌细胞中Annexin A1的表达。中国肺癌杂志。2012年第5期277-280页。
[91] Liu YF, Zhang PF, Li MY, Li QQ, Chen ZC. Identification of annexin A1as aproinvasive and prognostic factor for lung adenocarcinoma. Clin Exp Metastasis.2011Jun;28(5):413-25.
[92] Keenan J, Murphy L, Henry M, Meleady P, Clynes M. Proteomic analysis ofmultidrug-resistance mechanisms in adriamycin-resistant variants of DLKP, asquamous lung cancer cell line. Proteomics.2009Mar;9(6):1556-66.
[93] Qiu J, Choi G, Li L, Wang H, Pitteri SJ, Pereira-Faca SR, Krasnoselsky AL,Randolph TW, Omenn GS, Edelstein C, Barnett MJ, Thornquist MD, Goodman GE,Brenner DE, Feng Z, Hanash SM. Occurrence of autoantibodies to annexin I,14-3-3theta and LAMR1in prediagnostic lung cancer sera. J Clin Oncol.2008Nov1;26(31):5060-6.
[94] Brower V. Biomarker studies abound for early detection of lung cancer. J NatlCancer Inst.2009Jan7;101(1):11-3.
[95] Sharp JA, Waltham M, Williams ED, Henderson MA, Thompson EW. Transfectionof MDA-MB-231human breast carcinoma cells with bone sialoprotein (BSP)stimulates migration and invasion in vitro and growth of primary and secondarytumors in nude mice. Clin Exp Metastasis.2004;21(1):19-29.
[96] Sung V, Cattell DA, Bueno JM, Murray A, Zwiebel JA, Aaron AD, Thompson EW.Human breast cancer cell metastasis to long bone and soft organs of nude mice: aquantitative assay. Clin Exp Metastasis.1997Mar;15(2):173-83.
[97] Rubinson DA, Dillon CP, Kwiatkowski AV, Sievers C, Yang L, Kopinja J, RooneyDL, Zhang M, Ihrig MM, McManus MT, Gertler FB, Scott ML, Van Parijs L. Alentivirus-based system to functionally silence genes in primary mammalian cells,stem cells and transgenic mice by RNA interference. Nat Genet.2003Mar;33(3):401-6.
[98] Chiriva-Internati M, Grizzi F, Weidanz JA, Ferrari R, Yuefei Y, Velez B, ShearerMH, Lowe DB, Frezza EE, Cobos E, Kast WM, Kennedy RC. A NOD/SCID tumormodel for human ovarian cancer that allows tracking of tumor progression throughthe biomarker Sp17. J Immunol Methods.2007Apr10;321(1-2):86-93.
[99] Kakonen SM, Selander KS, Chirgwin JM, Yin JJ, Burns S, Rankin WA, Grubbs BG,Dallas M, Cui Y, Guise TA. Transforming growth factor-beta stimulates parathyroidhormone-related protein and osteolytic metastases via Smad and mitogen-activatedprotein kinase signaling pathways. J Biol Chem.2002Jul5;277(27):24571-8.
[100] ten Dijke P, Hill CS. New insights into TGF-β-Smad signalling. Trends BiochemSci.2004May;29(5):265-73.
[2] Lam WK, White NW, Chan-Yeung MM. Lung cancer epidemiology and risk factorsin Asia and Africa. Int J Tuberc Lung Dis.2004Sep;8(9):1045-57..
[3] Jackman DM, Johnson BE. Small-cell lung cancer. Lancet.2005Oct15-21;366(9494):1385-96.
[4] National Cancer Institute. SEER Cancer Statistics Review,1975–2006.http://seer.cancer.gov/csr/1975-2006(accessed Feb7,2011).
[5] Devesa SS, Bray F, Vizcaino AP, Parkin DM. International lung cancer trends byhistologic type: male: female differences diminishing and adenocarcinoma rising. IntJ Cancer.2005Nov1;117(2):294-9.
[6] Haddadin S, Perry MC. History of small-cell lung cancer. Clin Lung Cancer.2011Mar;12(2):87-93.
[7] Rove KO, Crawford ED. Metastatic cancer in solid tumors and clinical outcome:skeletal-related events. Oncology (Williston Park).2009Dec;23(14Suppl5):21-7.
[8]刘陶文，李俊喜。恶性肿瘤骨转移的诊断。华夏医学。2005年第6期1068-1069页。
[9]吴晓徽，陆汉魁。骨代谢指标在肿瘤骨转移诊治中的应用。肿瘤。2007年第6期505-507页。
[10] Sun JM, Ahn JS, Lee S, Kim JA, Lee J, Park YH, Park HC, Ahn MJ, Ahn YC, ParkK. Predictors of skeletal-related events in non-small cell lung cancer patients withbone metastases. Lung Cancer.2011Jan;71(1):89-93.
[11]李大为，王勤。骨转移癌的外科治疗。中医正骨。2007年第11期43-45页。
[12]陶衍能。恶性肿瘤骨转移的放射性治疗概况。医学文选。2006年第1期160-162页。
[13] Flanagan AM, Chambers TJ. Inhibition of bone resorption by bisphosphonates:interactions between bisphosphonates, osteoclasts, and bone. Calcif Tissue Int.1991Dec;49(6):407-15..
[14] Oades GM, Coxon J, Colston KW. The potential role of bisphosphonates in prostatecancer. Prostate Cancer Prostatic Dis.2002;5(4):264-72..
[15] Valachis A, Polyzos NP, Georgoulias V, Mavroudis D, Mauri D. Lack of evidencefor fracture prevention in early breast cancer bisphosphonate trials: a meta-analysis.Gynecol Oncol.2010Apr;117(1):139-45.
[16] King AE, Umland EM. Osteonecrosis of the jaw in patients receiving intravenous ororal bisphosphonates. Pharmacotherapy.2008May;28(5):667-77.
[17] Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, Lichinitser M,Fujiwara Y, Yardley DA, Viniegra M, Fan M, Jiang Q, Dansey R, Jun S, Braun A.Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastasesin Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study. JClin Oncol.2010Dec10;28(35):5132-9.
[18] Kaplan RN, Rafii S, Lyden D. Preparing the "soil": the premetastatic niche. CancerRes.2006Dec1;66(23):11089-93.
[19] Yin JJ, Pollock CB, Kelly K. Mechanisms of Cancer metastasis to the bone. CellRes.2005Jan;15(1):57-62.
[20] Yoneda T, Hiraga T. Crosstalk between cancer cells and bone microenvironment inbone metastasis. Biochem Biophys Res Commun.2005Mar18;328(3):679-87.
[21] Kingsley LA, Fournier PG, Chirgwin JM, Guise TA. Molecular biology of bonemetastasis. Mol Cancer Ther.2007Oct;6(10):2609-17.
[22] Acuff HB, Carter KJ, Fingleton B, Gorden DL, Matrisian LM. Matrixmetalloproteinase-9from bone marrow-derived cells contributes to survival but notgrowth of tumor cells in the lung microenvironment. Cancer Res.2006Jan1;66(1):259-66.
[23] Li M, Amizuka N, Takeuchi K, Freitas PH, Kawano Y, Hoshino M, Oda K,Nozawa-Inoue K, Maeda T. Histochemical evidence of osteoclastic degradation ofextracellular matrix in osteolytic metastasis originating from human lung smallcarcinoma(SBC-5)cells. Microsc Res Tech.2006Feb;69(2):73-83.
[24] Hsua CP, Shen GH, Ko JL. Matrix metalloproteinase-13expression is associatedwith bone marrow micro involvement and prognosis in non-small cell lung cancer.Lung Cancer.2006Jun;52(3):349-57.
[25]丁红仙。肿瘤免疫逃逸机制的研究进展。海峡药学。2008年第7期12-14页。
[26] Nakamura ES, Koizumi K, Kobayashi M, Saitoh Y, Arita Y, Nakayama T, SakuraiH, Yoshie O, Saiki I. RANKL2induced CCL22/macrop-hage2derived chemokineproduced from osteoclasts potentially promotes the bone metastasis of lung cancerexp ressing its receptor CCR4. Clin Exp Metastasis.2006;23(1):9-18.
[27] Phillips RJ, Burdick MD, Lutz M, Belperio JA, Keane MP, Strieter RM. Thestromal derived Factor1/CXCL12-CXC chemokine receptor-4biological axis innon small cell lung cancer metastases. Am J Respir Crit Care Med.2003Jun15;167(12):1676-86.
[28] Roodman GD. Mechanisms of bone metastasis. N Engl J Med.2004Apr15;350(16):1655-64.ngl J Med,2004,350(16):1655-1664.
[29] Martin TA, Harrison G, Mansel RE, Jiang WG. The role of the CD44／erzincomplex in cancer metastasis．Crit Rev Oncol Hematol.2003May;46(2):165-86.
[30] Hill A, McFarlane S, Johnston PG, Waugh DJ. The emerging role of CD44inregulating skeletal micrometastasis．Cancer Lett.2006Jun8;237(1):1-9.
[31] Felding-habermann B. Integrin adhesion receptors in tumor metastasis．Clin ExpMetastasis.2003;20(3):203-13.
[32] Li M, Amizuka N, Takeuchi K, Freitas PH, Kawano Y, Hoshino M, Oda K,Nozawa-Inoue K, Maeda T. Histochemical evidence of osteoclastic degradation ofextracellularmatrix in osteolytic metastasis originating from human lung smallcarcinoma (SBC-5) cells. Microsc Res Tech.2006Feb;69(2):73-83.
[33] Guise TA, Mohammad KS, Clines G, Stebbins EG, Wong DH, Higgins LS, VessellaR, Corey E, Padalecki S, Suva L, Chirgwin JM. Basic mechanisms responsible forosteolytic and osteoblastic bone metastases. Clin Cancer Res.2006Oct15;12(20Pt2):6213s-6216s.
[34] Roodman GD. Biology of osteoclast activation in cancer. J Clin Oncol.2001Aug1;19(15):3562-71.
[35] Guise TA, Yin JJ, Taylor SD, Kumagai Y, Dallas M, Boyce BF, Yoneda T, MundyGR. Evidence for a causal role of parathyroid hormone-related protein in thepathogenesis of human breast cancer-mediated osteoysis. J Clin Invest.1996Oct1;98(7):1544-9.
[36] Miki T, Yano S, Hanibuchi M, Kanematsu T, Muguruma H, Sone S. Parathyroidhormone-related protein (PTHrP) is responsible for production of bone metastasis,but not visceral metastasis, by human small cell lung Cancer SBC-5cells in naturalkiller cell-depleted SCID mice. Int J Cancer.2004Feb10;108(4):511-5.
[37] Cai Z, Chen Q, Chen J, Lu Y, Xiao G, Wu Z, Zhou Q, Zhang J. Monocytechemotactic protein1promotes lung cancer-induced bone resorptive lesions in vivo.Neoplasia.2009Mar;11(3):228-36.
[38] Choi SJ, Oba Y, Gazitt Y, Alsina M, Cruz J, Anderson J, Roodman GD. Antisenseinhibition of macrophage inflammatory protein1-alpha blocks bone destruction in amodel of myeloma bone disease. J Clin Invest.2001Dec;108(12):1833-41.
[39] Muguruma H, Yano S, Kakiuchi S, Uehara H, Kawatani M, Osada H, Sone S.Reveromycin A inhibits osteolytic bone metastasis of small cell lung cancer cells,SBC-5, through an antiosteoclastic activity. Clin Cancer Res.2005Dec15;11(24Pt1):8822-8.
[40] Miki T, Yano S, Hanibuchi M, Sone S. Bone metastasis model with multiorgandissemination of human small-cell lung Cancer (SBC-5) cells in natural killercell-depleted SCID mice. Oncol Res.2000;12(5):209-17.
[41] Zhang H, Yano S, Miki T, Goto H, Kanematsu T, Muguruma H, Uehara H, Sone S.A novel bisphosphonate minodronate (YM529) specifically inhibits osteolytic bonemetastasis produced by human small-cell lung cancer cells in NK-cell depletedSCID mice. Clin Exp Metastasis.2003;20(2):153-9.
[42] Yano S, Zhang H, Hanibuchi M, Miki T, Goto H, Uehara H, Sone S. CombinedTherapy with a New Bisphosphonate, Minodronate (YM529), and Chemotherapyfor Multiple Organ Metastases of Small Cell Lung Cancer Cells in Severe CombinedImmunodeficient Mice. Clin Cancer Res.2003Nov1;9(14):5380-5.
[43] Goto H, Yano S, Zhang H, Matsumori Y, Ogawa H, Blakey DC, Sone S. Activity ofa new vascular targeting agent, ZD6126, in pulmonary metastases by human lungadenocarcinoma in nude mice. Cancer Res.2002Jul1;62(13):3711-5.
[44] Zheng R, Yano S, Zhang H, Nakataki E, Tachibana I, Kawase I, Hayashi S, Sone S.CD9over-expression suppressed the liver metastasis and malignant ascites viainhibition of proliferation and motility of small-cell lung cancer cells in NKcell-depleted SCID mice. Oncol Res.2005;15(7-8):365-72.
[45] Fatimathas L，Moss SE．Annexins as disease modifiers．Histol Histopathol.2010Apr;25(4):527-32.
[46] Gerke V, Moss SE. Annexin: from structure to function. Physiol Rev.2002Apr;82(2):331-71.
[47] Gerke V, Creutz CE, Moss SE．Annexins：linking Ca2+signaling to membranedynamics．Nat Rev Mol Cell Biol.2005Jun;6(6):449-61.
[48] Flower RJ，Blackwell GJ．Antiinflammatory steroids induce biosynthesis of aphospholipase A2inhibitor which prevents prostaglandin generation．Nature.1979Mar29;278(5703):456-9.
[49] Kim SW, Rhee HJ, Ko J, Kim YJ, Kim HG, Yang JM, Choi EC, Na DS. Inhibitionof cytotoxic phospho lipase A2by annexin I: Specific interaction model andmapping of the interaction site. J Biol Chem.2001May11;276(19):15712-9.
[50] Croxtall JD, Choudhury Q, Flower RJ. Inhibitory effect of peptides derived from theN-terminus of lipocortin1on arachidonic acid release and proliferation in the A549cell line: identification of E-Q-E-Y-V as a crucial component. Br J Pharmacol.1998Mar;123(5):975-83.
[51] Ferlazzo V, D'Agostino P, Milano S, Caruso R, Feo S, Cillari E, Parente L.Anti-inflammatory effects of annexin1: stimulation of IL-10release and inhibitionof nitricoxide synthesis. Int Immunopharmacol.2003Oct;3(10-11):1363-9.
[52] Yona S, Ward B, Buckingham JC, Perretti M, Flower RJ. Macrophage biology inthe AnxA1-/-mouse. Prostaglandins Leukot Essent Fatty Acids.2005Feb;72(2):95-103.
[53] Chen Z, Yoshihara E, Son A, Matsuo Y, Masutani H, Sugie K, Maeda M, Yodoi J.Differential roles of Annexin A1(ANXA1/lipocortin-1/lipomodulin) andthioredoxin binding protein-2(TBP-2/VDUP1/TXNIP) in glucocorticoid signalingof HTLV-I-transformed T cells. Immunol Lett.2010Jun15;131(1):11-8.
[54] Hayhoe RP, Kamal AM, Solito E, Flower RJ, Cooper D, Perretti M. Annexin1andits bioactive peptide inhibit neutrophil-endothelium interactions under flow:indication of distinct receptor involvement. Blood.2006Mar1;107(5):2123-30.
[55] Rhee HJ, Kim GY, Huh JW, Kim SW, Na DS. Annexin I is a stress protein inducedby heat, oxidative stress and a sulfhydryl-reactive agent. Eur J Biochem.2000Jun;267(11):3220-5.
[56] Li G, He S, Chang L, Lu H, Zhang H, Zhang H, Chiu J. GADD45α and annexin A1are involved in the apoptosis of HL-60induced by resveratrol. Phytomedicine.2011Jun15;18(8-9):704-9.
[57] D'Acunto CW, Fontanella B, Rodriquez M, Taddei M, Parente L, Petrella A.Histone deacetylase inhibitor FR235222sensitizes human prostate adenocarcinomacells to apoptosis through up-regulation of Annexin A1. Cancer Lett.2010Sep1;295(1):85-91.
[58] Petrella A, Festa M, Ercolino SF, Zerilli M, Stassi G, Solito E, Parente L. Inductionof annexin-1during TRAIL-induced apoptosis in thyroid carcinoma cells. CellDeath Differ.2005Oct;12(10):1358-60.
[59] Patel DM, Ahmad SF, Weiss DG, Gerke V, Kuznetsov SA. Annexin A1is a newfunctional linker between actin filaments and phagosomes during phagocytosis. JCell Sci.2011Feb15;124(Pt4):578-88.
[60] Damazo AS, Sampaio AL, Nakata CM, Flower RJ, Perretti M, Oliani SM.Endogenous annexin A1counter-regulates bleomycin-induced lung fibrosis. BMCImmunol.2011Oct19;12:59..
[61] Dreier R, Schmid KW, Gerke V, Riehemann K. Differential expression of annexinⅠ, Ⅱand Ⅳ in human tissues: An immunohistochemical study. Histochem CellBiol.1998Aug;110(2):137-48..
[62] Bai XF, Ni XG, Zhao P, Liu SM, Wang HX, Guo B, Zhou LP, Liu F, Zhang JS,Wang K, Xie YQ, Shao YF, Zhao XH. Overexpression of annexin1in pancreaticcancer and its clinical significance. World J Gastroenterol.2004May15;10(10):1466-70.
[63] Falini B, Tiacci E, Liso A, Basso K, Sabattini E, Pacini R, Foa R, Pulsoni A, DallaFavera R, Pileri S. Simple diagnostic assay for hairy cell leukaemia byimmunocytochemical detection of annexin A1(ANXA1). Lancet.2004Jun5;363(9424):1869-70.
[64] Hummerich L, Müller R, Hess J, Kokocinski F, Hahn M, Fürstenberger G, Mauch C,Lichter P, Angel P. Identification of novel tumour-associated genes differentiallyexpressed in the process of squamous cell cancer development. Oncogene.2006Jan5;25(1):111-21.
[65] Schaeffer EM, Marchionni L, Huang Z, Simons B, Blackman A, Yu W, ParmigianiG, Berman DM. Androgen-induced programs for prostate epithelial growth andinvasion arise in embryogenesis and are reactivated in cancer. Oncogene.2008Dec4;27(57):7180-91.
[66] Xia SH, Hu LP, Hu H, Ying WT, Xu X, Cai Y, Han YL, Chen BS, Wei F, Qian XH,Cai YY, Shen Y, Wu M, Wang MR. Three isoforms of annexin I are preferentiallyexpressed in normal esophageal epithelia but downregulated in esophagealsquamous cell carcinomas. Oncogene.2002Sep26;21(43):6641-8.
[67] Garcia Pedrero JM, Fernandez MP, Morgan RO, Herrero Zapatero A, Gonzalez MV,Suarez Nieto C, Rodrigo JP. Annexin A1down-regulation in head and neck canceris associated with epithelial differentiation status. Am J Pathol.2004Jan;164(1):73-9.
[68] Koike H, Uzawa K, Nakashima D, Shimada K, Kato Y, Higo M, Kouzu Y, Endo Y,Kasamatsu A, Tanzawa H. Identification of differentially expressed proteins in oralsquamous cell carcinoma using a global proteomic approach. Int J Oncol.2005Jul;27(1):59-67.
[69] Silistino-Souza R, Rodrigues-Lisoni FC, Cury PM, Maniglia JV, Raposo LS, TajaraEH, Christian HC, Oliani SM. Annexin1: differential expression in tumor and mastcells in human larynx cancer. Int J Cancer.2007Jun15;120(12):2582-9.
[70] Shen D, Nooraie F, Elshimali Y, Lonsberry V, He J, Bose S, Chia D, Seligson D,Chang HR, Goodglick L. Decreased expression of annexin A1is correlated withbreast cancer development and progression as determined by a tissue microarrayanalysis. Hum Pathol.2006Dec;37(12):1583-91.
[71] Mussunoor S, Murray GI. The role of annexins in tumor development andprogression. J Pathol.2008Oct;216(2):131-40.
[72] Violette SM, King I, Browning JL, Pepinsky RB, Wallner BP, Sartorelli AC. Roleof lipocortin1in the glucocorticoid induction of the terminal differentiation of ahuman squamous carcinoma．Cell Physiol.1990Jan;142(1):70-7．
[73] Masaki T, Tokuda M, Ohnishi M, Watanabe S, Fujimura T, Miyamoto K, Itano T,Matsui H, Arima K, Shirai M, Maeba T, Sogawa K, Konishi R, Taniguchi K,Hatanaka Y, Hatase O, Nishioka M．Enhanced expression of the protein kinasesubstrate annexin in human hepatocellular carcinoma． Hepatology.1996Jul;24(1):72-81．
[74] Paweletz CP, Ornstein DK, Roth MJ, Bichsel VE, Gillespie JW, Calvert VS, VockeCD, Hewitt SM, Duray PH, Herring J, Wang QH, Hu N, Linehan WM, Taylor PR,Liotta LA, Emmert-Buck MR, Petricoin EF3rd．Loss of Annexin1correlates withearly onset of tumorigenesis in esophageal and prostate carcinoma．Cancer Res.2000Nov15;60(22):6293-7．
[75] Pencil SD, Toth M. Elevated levels of annexin I protein in vitro and in vivo in ratand human mammary adenocarcinoma. Clin Exp Metastasis.1998Feb;16(2):113-21.
[76] de Graauw M, van Miltenburg MH, Schmidt MK, Pont C, Lalai R, Kartopawiro J,Pardali E, Le Dévédec SE, Smit VT, van der Wal A, Van't Veer LJ, Cleton-JansenAM, ten Dijke P, van de Water B. Annexin A1regulates TGF-beta signaling andpromotes metastasis formation of basal-like breast cancer cells. Proc Natl Acad SciU S A.2010Apr6;107(14):6340-5.
[77] Cicek M, Samant RS, Kinter M, Welch DR, Casey G. Identification of metastasisassociated proteins through protein analysis of metastatic MDA-MB-435andmetastasis-suppressed BRMS1transfected MDA-MB-435cells. Clin Exp Metastasis.2004;21(2):149-57..
[78] Cao Y, Li Y, Edelweiss M, Arun B, Rosen D, Resetkova E, Wu Y, Liu J, Sahin A,Albarracin CT. Loss of annexin A1expression in breast cancer progression. ApplImmunohistochem Mol Morphol.2008Dec;16(6):530-4.
[79] Yu G, Wang J, Chen Y, Wang X, Pan J, Li Q, Xie K. Tissue microarray analysisreveals strong clinical evidence for a close association between loss of annexin A1expression and nodal metastasis in gastric cancer. Clin Exp Metastasis.2008;25(7):695-702..
[80]曲利娟，丁彦青，梁莉，余英豪。利用2-DE和MALDI-TOP-MS在人大肠癌高低转移潜能细胞株中筛选转移相关蛋白。福州总医院学报。2008年第B12期365-368页。
[81] Babbin BA, Lee WY, Parkos CA, Winfree LM, Akyildiz A, Perretti M, Nusrat A.AnxA1regulates SKCO-15cell invasion by signaling through formyl peptidereceptors. J Biol Chem.2006Jul14;281(28):19588-99.
[82]崔杰峰，刘银坤，代智，周海君，宋海燕，张丽君，张予，孙瑞霞，陈洁，汤钊猷。转移潜能不同人肝癌细胞系差异蛋白Annexin1的功能解析。生物化学与生物物理进展。2005年第12期1141-1149页。
[83] Wu W, Tang X, Hu W, Lotan R, Hong WK, Mao L. Identification and validation ofmetastasis-associated proteins in head and neck cancer cell lines by two-dimensionalelectrophoresis and mass spectrometry. Clin Exp Metastasis.2002;19(4):319-26.
[84] Rondepierre F, Bouchon B, Papon J, Bonnet-Duquennoy M, Kintossou R, Moins N,Maublant J, Madelmont JC, D'Incan M, Degoul F. Proteomic studies of B16lines:Involvement of Annexin A1in melanoma dissemination. Biochim Biophys Acta.2009Jan;1794(1):61-9.
[85] Cheng AL, Huang WG, Chen ZC, Peng F, Zhang PF, Li MY, Li F, Li JL, Li C, Yi H,Yi B, Xiao ZQ. Identification of Novel Nasopharyngeal Carcinoma Biomarkers byLaser Capture Microdissection and Proteomic Analysis. Clin Cancer Res.2008Jan15;14(2):435-45.
[86] Zimmermann U, Woenckhaus C, Teller S, Venz S, Langheinrich M, Protzel C,Maile S, Junker H, Giebel J. Expression of annexin A1in conventional renal cellcarcinoma (CRCC) correlates with tumour stage, Fuhrman grade, amount ofeosinophilic cells and clinical outcome. Histol Histopathol.2007May;22(5):527-34.
[87] Wang Y, Serfass L, Roy MO, Wong J, Bonneau AM, Georges E. Annexin-Iexpression modulates drug resistance in tumor cells. Biochem Biophys ResCommun.2004Feb6;314(2):565-70.
[88] Wang KL, Wu TT, Resetkova E, Wang H, Correa AM, Hofstetter WL, Swisher SG,Ajani JA, Rashid A, Hamilton SR, Albarracin CT. Expression of annexin A1inesophageal and esophagogastric junction adenocarcinomas:association with pooroutcome． Clin Cancer Res.2006Aug1;12(15):4598-604．
[89] Biaoxue R, Xiling J, Shuanying Y, Wei Z, Xiguang C, Jinsui W, Min Z.Upregulation of Hsp90-beta and annexin A1correlates with poor survival andlymphatic metastasis in lung cancer patients. J Exp Clin Cancer Res.2012Aug28;31:70.
[90]胡振红，黄瑊，李振华，李晓栩，傅祖红，刘海潮，官立彬。低氧上调肺腺癌细胞中Annexin A1的表达。中国肺癌杂志。2012年第5期277-280页。
[91] Liu YF, Zhang PF, Li MY, Li QQ, Chen ZC. Identification of annexin A1as aproinvasive and prognostic factor for lung adenocarcinoma. Clin Exp Metastasis.2011Jun;28(5):413-25.
[92] Keenan J, Murphy L, Henry M, Meleady P, Clynes M. Proteomic analysis ofmultidrug-resistance mechanisms in adriamycin-resistant variants of DLKP, asquamous lung cancer cell line. Proteomics.2009Mar;9(6):1556-66.
[93] Qiu J, Choi G, Li L, Wang H, Pitteri SJ, Pereira-Faca SR, Krasnoselsky AL,Randolph TW, Omenn GS, Edelstein C, Barnett MJ, Thornquist MD, Goodman GE,Brenner DE, Feng Z, Hanash SM. Occurrence of autoantibodies to annexin I,14-3-3theta and LAMR1in prediagnostic lung cancer sera. J Clin Oncol.2008Nov1;26(31):5060-6.
[94] Brower V. Biomarker studies abound for early detection of lung cancer. J NatlCancer Inst.2009Jan7;101(1):11-3.
[95] Sharp JA, Waltham M, Williams ED, Henderson MA, Thompson EW. Transfectionof MDA-MB-231human breast carcinoma cells with bone sialoprotein (BSP)stimulates migration and invasion in vitro and growth of primary and secondarytumors in nude mice. Clin Exp Metastasis.2004;21(1):19-29.
[96] Sung V, Cattell DA, Bueno JM, Murray A, Zwiebel JA, Aaron AD, Thompson EW.Human breast cancer cell metastasis to long bone and soft organs of nude mice: aquantitative assay. Clin Exp Metastasis.1997Mar;15(2):173-83.
[97] Rubinson DA, Dillon CP, Kwiatkowski AV, Sievers C, Yang L, Kopinja J, RooneyDL, Zhang M, Ihrig MM, McManus MT, Gertler FB, Scott ML, Van Parijs L. Alentivirus-based system to functionally silence genes in primary mammalian cells,stem cells and transgenic mice by RNA interference. Nat Genet.2003Mar;33(3):401-6.
[98] Chiriva-Internati M, Grizzi F, Weidanz JA, Ferrari R, Yuefei Y, Velez B, ShearerMH, Lowe DB, Frezza EE, Cobos E, Kast WM, Kennedy RC. A NOD/SCID tumormodel for human ovarian cancer that allows tracking of tumor progression throughthe biomarker Sp17. J Immunol Methods.2007Apr10;321(1-2):86-93.
[99] Kakonen SM, Selander KS, Chirgwin JM, Yin JJ, Burns S, Rankin WA, Grubbs BG,Dallas M, Cui Y, Guise TA. Transforming growth factor-beta stimulates parathyroidhormone-related protein and osteolytic metastases via Smad and mitogen-activatedprotein kinase signaling pathways. J Biol Chem.2002Jul5;277(27):24571-8.
[100] ten Dijke P, Hill CS. New insights into TGF-β-Smad signalling. Trends BiochemSci.2004May;29(5):265-73.